(RELX) Relx - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US7595301083
Stock:
Total Rating 38
Risk 70
Buy Signal -1.35
| Risk 5d forecast | |
|---|---|
| Volatility | 32.1% |
| Relative Tail Risk | 2.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.57 |
| Alpha | -47.17 |
| Character TTM | |
|---|---|
| Beta | 0.503 |
| Beta Downside | 0.079 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.91% |
| CAGR/Max DD | 0.04 |
Description: RELX Relx
RELX PLC, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Risk; Scientific, Technical & Medical; Legal; and Exhibitions. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. The Scientific, Technical & Medical segment provides scientific and medical information and data sets that help researchers and healthcare professionals to advance science and health outcomes. The Legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as increases the productivity. The Exhibitions segment is involved in the business that combines face-to-face with data and digital tools to help customers learn about markets, source products, and transactions. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. RELX PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.99b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.37 > 0.02 and ΔFCF/TA 16.54 > 1.0 |
| NWC/Revenue: -15.94% < 20% (prev -18.93%; Δ 2.99% < -1%) |
| CFO/TA 0.37 > 3% & CFO 5.51b > Net Income 3.99b |
| Net Debt (7.19b) to EBITDA (6.05b): 1.19 < 3 |
| Current Ratio: 0.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.83b) vs 12m ago -3.31% < -2% |
| Gross Margin: 65.00% > 18% (prev 0.62%; Δ 6439 % > 0.5%) |
| Asset Turnover: 128.1% > 50% (prev 92.14%; Δ 35.99% > 0%) |
| Interest Coverage Ratio: 7.66 > 6 (EBITDA TTM 6.05b / Interest Expense TTM 568.5m) |
Altman Z'' 1.08
| A: -0.21 (Total Current Assets 2.95b - Total Current Liabilities 5.98b) / Total Assets 14.73b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.73b) |
| C: 0.29 (EBIT TTM 4.35b / Avg Total Assets 14.82b) |
| D: 0.03 (Book Value of Equity 392.3m / Total Liabilities 12.35b) |
| Altman-Z'' Score: 1.08 = BB |
Beneish M -3.10
| DSRI: 0.77 (Receivables 2.46b/2.32b, Revenue 18.99b/13.74b) |
| GMI: 0.95 (GM 65.00% / 61.53%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.79) |
| SGI: 1.38 (Revenue 18.99b / 13.74b) |
| TATA: -0.10 (NI 3.99b - CFO 5.51b) / TA 14.73b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of RELX shares?
As of February 25, 2026, the stock is trading at USD 30.50 with a total of 3,742,406 shares traded.
Over the past week, the price has changed by +0.16%, over one month by -23.56%, over three months by -24.41% and over the past year by -37.01%.
Over the past week, the price has changed by +0.16%, over one month by -23.56%, over three months by -24.41% and over the past year by -37.01%.
Is RELX a buy, sell or hold?
Relx has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy RELX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RELX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.5 | 68.9% |
| Analysts Target Price | 51.5 | 68.9% |
RELX Fundamental Data Overview February 20, 2026
P/E Trailing = 20.3882
P/E Forward = 16.0514
P/S = 5.8424
P/B = 17.4289
P/EG = 1.5154
Revenue TTM = 18.99b USD
EBIT TTM = 4.35b USD
EBITDA TTM = 6.05b USD
Long Term Debt = 5.53b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 7.32b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b USD (from netDebt column, last quarter)
Enterprise Value = 63.22b USD (56.03b + Debt 7.32b - CCE 130.8m)
Interest Coverage Ratio = 7.66 (Ebit TTM 4.35b / Interest Expense TTM 568.5m)
EV/FCF = 11.56x (Enterprise Value 63.22b / FCF TTM 5.47b)
FCF Yield = 8.65% (FCF TTM 5.47b / Enterprise Value 63.22b)
FCF Margin = 28.80% (FCF TTM 5.47b / Revenue TTM 18.99b)
Net Margin = 21.02% (Net Income TTM 3.99b / Revenue TTM 18.99b)
Gross Margin = 65.00% ((Revenue TTM 18.99b - Cost of Revenue TTM 6.65b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 4.29 (Enterprise Value 63.22b / Total Assets 14.73b)
Interest Expense / Debt = 1.07% (Interest Expense 78.5m / Debt 7.32b)
Taxrate = 25.09% (365.7m / 1.46b)
NOPAT = 3.26b (EBIT 4.35b * (1 - 25.09%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.10 (Debt 7.32b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.19 (Net Debt 7.19b / EBITDA 6.05b)
Debt / FCF = 1.31 (Net Debt 7.19b / FCF TTM 5.47b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.93% (Net Income 3.99b / Total Assets 14.73b)
RoE = 142.1% (Net Income TTM 3.99b / Total Stockholder Equity 2.81b)
RoCE = 52.23% (EBIT 4.35b / Capital Employed (Equity 2.81b + L.T.Debt 5.53b))
RoIC = 33.08% (NOPAT 3.26b / Invested Capital 9.86b)
WACC = 6.96% (E(56.03b)/V(63.35b) * Re(7.77%) + D(7.32b)/V(63.35b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.67%
[DCF Debug] Terminal Value 84.71% ; FCFF base≈4.51b ; Y1≈5.56b ; Y5≈9.48b
Fair Price DCF = 107.9 (EV 202.26b - Net Debt 7.19b = Equity 195.07b / Shares 1.81b; r=6.96% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.61 | Revenue CAGR: 12.26% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.96 | Chg30d=+0.054 | Revisions Net=-1 | Growth EPS=+12.5% | Growth Revenue=+5.6%
EPS next Year (2027-12-31): EPS=2.21 | Chg30d=+0.142 | Revisions Net=+1 | Growth EPS=+12.6% | Growth Revenue=+6.8%
P/E Forward = 16.0514
P/S = 5.8424
P/B = 17.4289
P/EG = 1.5154
Revenue TTM = 18.99b USD
EBIT TTM = 4.35b USD
EBITDA TTM = 6.05b USD
Long Term Debt = 5.53b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 7.32b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b USD (from netDebt column, last quarter)
Enterprise Value = 63.22b USD (56.03b + Debt 7.32b - CCE 130.8m)
Interest Coverage Ratio = 7.66 (Ebit TTM 4.35b / Interest Expense TTM 568.5m)
EV/FCF = 11.56x (Enterprise Value 63.22b / FCF TTM 5.47b)
FCF Yield = 8.65% (FCF TTM 5.47b / Enterprise Value 63.22b)
FCF Margin = 28.80% (FCF TTM 5.47b / Revenue TTM 18.99b)
Net Margin = 21.02% (Net Income TTM 3.99b / Revenue TTM 18.99b)
Gross Margin = 65.00% ((Revenue TTM 18.99b - Cost of Revenue TTM 6.65b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 4.29 (Enterprise Value 63.22b / Total Assets 14.73b)
Interest Expense / Debt = 1.07% (Interest Expense 78.5m / Debt 7.32b)
Taxrate = 25.09% (365.7m / 1.46b)
NOPAT = 3.26b (EBIT 4.35b * (1 - 25.09%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.10 (Debt 7.32b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.19 (Net Debt 7.19b / EBITDA 6.05b)
Debt / FCF = 1.31 (Net Debt 7.19b / FCF TTM 5.47b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.93% (Net Income 3.99b / Total Assets 14.73b)
RoE = 142.1% (Net Income TTM 3.99b / Total Stockholder Equity 2.81b)
RoCE = 52.23% (EBIT 4.35b / Capital Employed (Equity 2.81b + L.T.Debt 5.53b))
RoIC = 33.08% (NOPAT 3.26b / Invested Capital 9.86b)
WACC = 6.96% (E(56.03b)/V(63.35b) * Re(7.77%) + D(7.32b)/V(63.35b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.67%
[DCF Debug] Terminal Value 84.71% ; FCFF base≈4.51b ; Y1≈5.56b ; Y5≈9.48b
Fair Price DCF = 107.9 (EV 202.26b - Net Debt 7.19b = Equity 195.07b / Shares 1.81b; r=6.96% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.61 | Revenue CAGR: 12.26% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.96 | Chg30d=+0.054 | Revisions Net=-1 | Growth EPS=+12.5% | Growth Revenue=+5.6%
EPS next Year (2027-12-31): EPS=2.21 | Chg30d=+0.142 | Revisions Net=+1 | Growth EPS=+12.6% | Growth Revenue=+6.8%